- Reaction score
- 96
One of the main selling points of cortexolone 17-a propionate, aka CB-03-01, aka Winlevi, aka Breezula, is its safety profile.
Winlevi phase 1: "showed no measurable side effects"
Winlevi phase 2: "No clinically relevant safety issues were noted with any of the concentrations of Winlevi™ tested and no clinically relevant signs of the typical LSR generally associated with corticosteroids use were appreciated. In the HPA/PK study only 3 out of 42 subjects resulted borderline in the lab test relevant to HP axis, with no sign of clinical corticosteroid specific adverse events."
http://www.cassiopea.com/activities/product-pipeline/winlevi.aspx
Breezula: "Breezula™ does not interfere with the hormonal and, in particular, androgenic profile of patients; libido and sexual behavior are unaffected in clinical trials to date. Because the API of Breezula™ is the same as that of Winlevi™, both product candidates have the same safety profile. Although Breezula™ has a higher concentration of this API, because the scalp is less permeable than facial skin, the systemic penetration of the two product candidates is substantially the same."
http://www.cassiopea.com/activities/product-pipeline/breezula.aspx
There are two proposed reasons for why CB has few side effects. The first: "CB-03-01 might poorly penetrate the blood brain barrier, thus failing to achieve adequate concentration in CNS."
https://www.researchgate.net/public...nd_Peripherally_Selective_Androgen_Antagonist
The second, and more popular, is that CB is "rapidly" hydrolyzed to cortexolone, which does not have an anti-androgenic effect. This is the idea that Cosmo/Cassiopeia has run with since the study cited above, one of the first about CB.
However, what is extremely important, the point of this thread, is to understand the significance of how quickly this hydrolysis occurs. The metabolism of CB. In every single article about CB, for acne or alopecia (found all of them on JAAD), they all claim that CB is "rapidly metabolized" but don't mention how rapidly. So I purchased the "biological profile" study cited from researchgate, because it was the first to use these terms, and lay out the alternative hypothesis that they have now neglected. But even that text, in full, does not explain how/how quickly CB is metabolized.
According to the Merck Manual, on the topic of drugs in the circulatory system: "After a drug is absorbed into the bloodstream, it rapidly circulates through the body. The average circulation time of blood is 1 minute. As the blood recirculates, the drug moves from the bloodstream into the body’s tissues."
http://www.merckmanuals.com/home/drugs/administration-and-kinetics-of-drugs/drug-distribution
So, if a drug can take 1 minute to spread around the entire body, it will probably only take a fraction of a second to move from your scalp to your face. If you have thinning side hair/side burns and apply CB to treat Androgenetic Alopecia, CB could reach your facial hair in less than a second. It might take only a few seconds to move from your scalp to your chest tissue.
Now, it does seem that the clinical trials have supported that this doesn't happen. Gynecomastia and facial hair loss haven't been reported as far as I have read. But I think we should still be cautious. CB is a powerful anti-androgen. There is nothing about the drug that would inhibit it from inducing classic AA side effects IF the unmetabolized drug made it to those tissues.
So if the clinical trials haven't shown these side effects, what does this mean? Is CB metabolized within a microsecond? Is this even possible? How could this be tested?
If this information had been pursued/released already, I'd probably already be taking this drug. But it's still an anti-androgen, and I'd like to know more about it. Any way we could test this? I'd appreciate your guys' input.
Winlevi phase 1: "showed no measurable side effects"
Winlevi phase 2: "No clinically relevant safety issues were noted with any of the concentrations of Winlevi™ tested and no clinically relevant signs of the typical LSR generally associated with corticosteroids use were appreciated. In the HPA/PK study only 3 out of 42 subjects resulted borderline in the lab test relevant to HP axis, with no sign of clinical corticosteroid specific adverse events."
http://www.cassiopea.com/activities/product-pipeline/winlevi.aspx
Breezula: "Breezula™ does not interfere with the hormonal and, in particular, androgenic profile of patients; libido and sexual behavior are unaffected in clinical trials to date. Because the API of Breezula™ is the same as that of Winlevi™, both product candidates have the same safety profile. Although Breezula™ has a higher concentration of this API, because the scalp is less permeable than facial skin, the systemic penetration of the two product candidates is substantially the same."
http://www.cassiopea.com/activities/product-pipeline/breezula.aspx
There are two proposed reasons for why CB has few side effects. The first: "CB-03-01 might poorly penetrate the blood brain barrier, thus failing to achieve adequate concentration in CNS."
https://www.researchgate.net/public...nd_Peripherally_Selective_Androgen_Antagonist
The second, and more popular, is that CB is "rapidly" hydrolyzed to cortexolone, which does not have an anti-androgenic effect. This is the idea that Cosmo/Cassiopeia has run with since the study cited above, one of the first about CB.
However, what is extremely important, the point of this thread, is to understand the significance of how quickly this hydrolysis occurs. The metabolism of CB. In every single article about CB, for acne or alopecia (found all of them on JAAD), they all claim that CB is "rapidly metabolized" but don't mention how rapidly. So I purchased the "biological profile" study cited from researchgate, because it was the first to use these terms, and lay out the alternative hypothesis that they have now neglected. But even that text, in full, does not explain how/how quickly CB is metabolized.
According to the Merck Manual, on the topic of drugs in the circulatory system: "After a drug is absorbed into the bloodstream, it rapidly circulates through the body. The average circulation time of blood is 1 minute. As the blood recirculates, the drug moves from the bloodstream into the body’s tissues."
http://www.merckmanuals.com/home/drugs/administration-and-kinetics-of-drugs/drug-distribution
So, if a drug can take 1 minute to spread around the entire body, it will probably only take a fraction of a second to move from your scalp to your face. If you have thinning side hair/side burns and apply CB to treat Androgenetic Alopecia, CB could reach your facial hair in less than a second. It might take only a few seconds to move from your scalp to your chest tissue.
Now, it does seem that the clinical trials have supported that this doesn't happen. Gynecomastia and facial hair loss haven't been reported as far as I have read. But I think we should still be cautious. CB is a powerful anti-androgen. There is nothing about the drug that would inhibit it from inducing classic AA side effects IF the unmetabolized drug made it to those tissues.
So if the clinical trials haven't shown these side effects, what does this mean? Is CB metabolized within a microsecond? Is this even possible? How could this be tested?
If this information had been pursued/released already, I'd probably already be taking this drug. But it's still an anti-androgen, and I'd like to know more about it. Any way we could test this? I'd appreciate your guys' input.